ArticleTranslational cancer research2026
Multiomic characterization of response and resistance to neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In neoadjuvant chemoradiotherapy (NCRT), only 1/3 of patients with esophageal squamous cell carcinoma (ESCC) achieve pathologic complete response (pCR). Here, we aimed to depict the biological landscape of ESCC with different responses to NCRT and identify biomarkers to facilitate clinical decision-making. Methods: Tumor specimens before NCRT were obtained for whole exome sequencing (WES), RNA sequencing, and data-independent acquisition (DIA) mass spectrometry. Genomic data were analyzed for significantly mutated genes (SMGs), copy number alterations, microsatellite instability (MSI), tumor mutation burden (TMB), and mutational signatures. Transcriptomic and proteomic data were used to examine differentially activated pathways. Gene set enrichment analysis (GSEA) and ActivePathways were used for single omics and joint multiomics analyses, respectively. Treatment-resistance biomarkers were identified and confirmed in a separate cohort using immunohistochemistry (IHC). Results: FBXW7 mutation (Fisher's exact test, P=0.03) and 9p21.3 cytoband loss (q-value =0.001) are the significant genetic variations in the pCR group. Combined transcriptomic and proteomic analyses revealed that the type I interferon signaling pathways and retinoic acid-inducible gene I (RIG-I)-like receptor (RLR) signaling pathways were enriched in non-pCR tumors. A biomarker panel of 12 proteins predictive of non-pCR tumors was identified, 10 of which were verified using multiplex IHC (mIHC) in an independent cohort. Conclusions: We described the multiomic biological characteristics of ESCC with distinct responses to NCRT and proposed a panel of proteins as predictive biomarkers for non-pCR patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.